藥明生物(02269.HK)採納全球合夥人計劃的股份獎勵計劃
格隆匯6月17日丨藥明生物(02269.HK)公佈,於2021年6月16日,公司已採納全球合夥人股份獎勵計劃,以進一步獎勵及激勵集團的頂尖僱員並吸引關鍵人才,確保公司的持續業務發展及增長。截至本公吿日期,公司亦已採納適用於集團全體僱員的受限制股份獎勵計劃。為進一步使頂尖僱員的利益與公司股東保持一致,對集團業務發展及增長作出重大貢獻的選定參與者將根據全球合夥人股份獎勵計劃獲授受限制股份。因此,將予授出的受限制股份數目及其價值將根據多項與表現相關的考慮因素釐定,例如各選定參與者達成其個人表現目標以及集團的整體業務表現。
所有根據全球合夥人股份獎勵計劃授出的相關受限制股份總數不得超過公司於採納日期的已發行股份總數的3%(即1.27億股股份)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.